Phase I extension study demonstrates beneficial effects on lipid metabolism with C21

Vicore Pharma AB (publ) (ticker: VICO) can today announce positive results from the in-depth analysis of the Phase I extension study with its candidate drug named C21.The extension study, initiated in January 2017, was performed on a group of overweight (BMI 30-35 and waist-to-hip ratio (WHR) above 0.9) but otherwise healthy men. In total 16 volunteers participated, whereof 8 were given 100 mg C21 in a once daily dose and 8 were given placebo over a period of 8 days. The aim of the study was to evaluate safety and tolerability of C21 in a group with a potentially compromised metabolic